Skip to main content

Autolus Therapeutics Receives Prix Galien UK Award

Written by Customer Service on . Posted in Public Companies.

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare. 

“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become a reality. This award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients,” said Dr. Martin Pule, Founder and Chief Scientific Officer of Autolus, Clinical Senior Lecturer in the Department of Haematology at the UCL Cancer Institute, and Honorary Consultant in Haematology at University College London Hospital.

About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
Executive Director, Investor Relations & External Communications
+1 617-967-0207 
a.cray@autolus.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.